Ben Teh
@benwteh.bsky.social
📤 290
📥 85
📝 14
ID physician & Clinician researcher
@petermaccc.bsky.social
#TxID
#Haem
#Vaccination
reposted by
Ben Teh
about 1 month ago
Challenging CMV Cases in Solid Organ Transplant Recipients Wednesday 15 October 2025 6.00pm - 7.30pm Presenters: Helen Tang (RPAH) Jenny Li (Alfred) Becky Lane (ADHB) To register click
asidevents.eventsair.com/cmv-webinars...
.
loading . . .
CMV #2 Webinar
https://asidevents.eventsair.com/cmv-webinars/cmv2webinar
0
0
1
reposted by
Ben Teh
about 1 month ago
ASID is hosting two webinars on CMV thanks to the support of Takeda Educational Grant. Challenging CMV Cases in Hematologic Stem Cell Transplant Recipients and Patients with Hematologic Malignancies Wednesday 17 September 6.00pm - 7.30pm To register -
asidevents.eventsair.com/cmv-webinars...
loading . . .
CMV #1 Webinar Registration
https://asidevents.eventsair.com/cmv-webinars/cmv1webinar
1
0
1
reposted by
Ben Teh
The Lancet Infectious Diseases
2 months ago
Paper 2-Innovation in active and passive immunisation of people who are immunocompromised: a call to action
www.thelancet.com/journals/lan...
loading . . .
Innovation in active and passive immunisation of people who are immunocompromised: a call to action
The proportion of the population with immunocompromising conditions, who are at increased risk for complications from infectious diseases, continues to grow. Concurrently, outbreaks due to known and e...
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00345-7/fulltext
1
1
1
More critical than ever -
@ncicancer.bsky.social
@petermaccc.bsky.social
#TxID
Innovation in active and passive immunisation of people who are immunocompromised: a call to action - The Lancet Infectious Diseases
www.thelancet.com/journals/lan...
loading . . .
Innovation in active and passive immunisation of people who are immunocompromised: a call to action
The proportion of the population with immunocompromising conditions, who are at increased risk for complications from infectious diseases, continues to grow. Concurrently, outbreaks due to known and e...
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2825%2900345-7/fulltext
2 months ago
0
2
0
Delighted to have been part of these important ECiL-10 c diff guidelines specific to our haematology patients.
#TxID
@ncicancer.bsky.social
@ichs-global.bsky.social
@theebmt.bsky.social
www.sciencedirect.com/science/arti...
loading . . .
ScienceDirect.com | Science, health and medical journals, full text articles and books.
https://smex-ctp.trendmicro.com/wis/clicktime/v1/query?url=https%3a%2f%2fkwnsfk27.r.eu%2dwest%2d1.awstrack.me%2fL0%2fhttps%3a%252F%252Fauthors.elsevier.com%252Fsd%252Farticle%252FS2589537025003037%2f1%2f010201988635f42a%2d4be93c7a%2d0010%2d4c3b%2d92c1%2db09e88e40569%2d000000%2fUpjmKZCmDFYLAIebemrrc4xVbcA%3d438&umid=3c6f1756-f236-4fdd-99b8-41327f30618e&auth=2af5473c4b03509246eb08bd803a6cf835f69953-3a071b88f9e4257b689fc3e0159d03f8564c2821
2 months ago
1
2
1
Huge thanks to haem cancer consumers for guiding us on how to improve delivery of vaccination. Uptake is key!
#TxID
@ncicancer.bsky.social
url.au.m.mimecastprotect.com/s/R9OxCK1qwB...
loading . . .
ScienceDirect.com | Science, health and medical journals, full text articles and books.
https://url.au.m.mimecastprotect.com/s/R9OxCK1qwBSDKQOG0S3iri5bDU2?domain=kwnsfk27.r.eu-west-1.awstrack.me
3 months ago
1
1
0
Influenza-Specific T-Cell Responses to Vaccination Are Independent of Underlying Hematological Malignancy: Analysis of a Randomized Influenza Vaccination Trial url:
academic.oup.com/jid/article-...
loading . . .
Influenza-Specific T-Cell Responses to Vaccination Are Independent of Underlying Hematological Malignancy: Analysis of a Randomized Influenza Vaccination Trial
In an in-depth immunological analysis of alternate influenza vaccination strategies in high-risk patients receiving therapy for hematological malignancy, p
https://academic.oup.com/jid/article-abstract/doi/10.1093/infdis/jiaf297/8178477
3 months ago
1
5
3
The national update on vaccination in immunocompromised is out! Delighted to have contributed to this.
#TxID
loading . . .
https://immunisationhandbook.health.gov.au/contents/vaccination-for-special-risk-groups/vaccination-for-people-who-are-immunocompromised
5 months ago
0
3
0
It was very lovely of
@joshhillmd.bsky.social
to highlight our trial in his top 10 papers at
#escmidglobal
www.nejm.org/doi/abs/10.1...
6 months ago
1
2
0
reposted by
Ben Teh
NCICancer
6 months ago
We are excited for
#ESCMIDGLOBAL
- the premier event for Infectious Diseases and Microbiology hosted by
@escmid.bsky.social
in Vienna, Austria! 🌍 If you're planning to attend, we’d love to connect with you. Below are the details of our presentations, including titles, times, and locations.
2
4
3
reposted by
Ben Teh
Priya Garg
6 months ago
Honoured to speak & present our
@ncicancer.bsky.social
work on infection prevention in cancer/transplant at the Australasian Society of ID ASM with
@nikhil-singh.bsky.social
@michyong.bsky.social
@benwteh.bsky.social
, & amazing to hear & see the incredible work done at other centres nationally 👏🏽
2
8
2
reposted by
Ben Teh
Michael G. Ison, MD MS
7 months ago
Vaccines are critical for the protection of patients from infection - it was an honor to write this piece discussing the challenges and data needs for use in immunocompromised patients.
academic.oup.com/jid/article/...
loading . . .
Vaccines for Use in Special Populations: Immunocompromised Hosts
The proportion of immunocompromised individuals in the United States has grown rapidly and currently accounts for 6.6% of the US population [1]. Individual
https://academic.oup.com/jid/article/231/3/552/7821592?utm_source=etoc&utm_campaign=jid&utm_medium=email
0
15
6
reposted by
Ben Teh
NCICancer
8 months ago
Join us at the 15th Febrile Neutropenia Symposium, taking place online on March 15–16, 2025! NCIC Researcher,
@benwteh.bsky.social
, will present on 'Standardised Reporting of Infection Events in Immunocompromised Patients.' To learn more and sign up:
cdn.wildapricot.com/24830/resour...
1
3
1
What drives or discourages our haematology patients from getting vaccinated. Lovely collab with HSR team
@petermaccc.bsky.social
www.sciencedirect.com/science/arti...
#TxID
#HaemOncID
loading . . .
“It's a risk-benefit analysis”: Qualitative perspectives on barriers and enablers to post-treatment vaccination from adults affected by a haematological malignancy in Australia
People affected by haematological malignancies are at high risk of morbidity and mortality caused by vaccine-preventable infections. However, vaccinat…
https://www.sciencedirect.com/science/article/pii/S0264410X25001239?dgcid=coauthor
8 months ago
0
2
0
reposted by
Ben Teh
Michael G. Ison, MD MS
8 months ago
We need anyone interested in reviewing for the journal to use this survey to submit interest. This will help us better tailor papers we send to you for review! Even if you are already reviewing for us, would encourage you to submit your preference.
#IDSky
add a skeleton here at some point
0
10
5
reposted by
Ben Teh
NEJM.org
9 months ago
In this trial involving patients with hematologic cancers, the immune responses that were elicited were similar for adjuvanted-dose and standard-dose influenza vaccines. Read the full trial results:
nej.md/40ztLNF
#MedSky
#IDSky
#Oncology
loading . . .
Influenza Vaccination Strategies in Patients with Hematologic Cancer | NEJM
In this trial involving patients with hematologic cancers, the immune responses that were elicited were similar for adjuvanted-dose and standard-dose influenza vaccines.
https://nej.md/40ztLNF
0
22
11
reposted by
Ben Teh
Tori Hall
9 months ago
Very proud of this hard work & team effort from all involved! Limited benefit of adjuvanted flu 💉 & 2 vs 1 dose in pts w/ MM, CLL or NHL.
@ncicancer.bsky.social
@petermaccc.bsky.social
@benwteh.bsky.social
@trubianojason.bsky.social
@michyong.bsky.social
@nejm.org
www.nejm.org/doi/full/10....
loading . . .
Influenza Vaccination Strategies in Patients with Hematologic Cancer | NEJM
In this trial involving patients with hematologic cancers, the immune responses that were elicited were similar for adjuvanted-dose and standard-dose influenza vaccines.
https://www.nejm.org/doi/full/10.1056/NEJMc2406750
2
9
6
Practice affirming results from our team
@victoriahall.bsky.social
@ncicancer.bsky.social
- No additional benefit from second influenza vaccine dose/adjuvant vaccines in non-HCT haematology patients.
#TxID
#IDsky
#medsky
www.nejm.org/doi/full/10....
loading . . .
Influenza Vaccination Strategies in Patients with Hematologic Cancer | NEJM
In this trial involving patients with hematologic cancers, the immune responses that were elicited were similar for adjuvanted-dose and standard-dose influenza vaccines.
https://www.nejm.org/doi/full/10.1056/NEJMc2406750
9 months ago
0
17
7
reposted by
Ben Teh
Clinical Infectious Diseases
10 months ago
Glucocorticoid dosing and implications for vaccination: Evolution of global definitions ✅ Just Accepted
#IDSky
loading . . .
Glucocorticoid dosing and implications for vaccination: Evolution of global definitions
Despite widespread adoption of “high-dose” glucocorticoid definitions across international immunisation guidelines (i.e., prednisone-equivalent dosing >20 mg/day, or >2 mg/kg/day in children), the rationale remains unclear. Literature searches were performed through academic databases for this narrative review to identify relevant evidence regarding glucocorticoid dosing on vaccine responses and safety.
https://buff.ly/4fwFUHg
0
15
4
you reached the end!!
feeds!
log in
